Artificial Lung

Artificial Lung Market Outlook

The global artificial lung market is projected to reach approximately USD 4.5 billion by 2033, expanding at a robust CAGR of around 14.5% during the forecast period from 2025 to 2033. This significant growth can be attributed to the increasing prevalence of chronic respiratory diseases, advancements in lung support technologies, and a growing aging population requiring respiratory assistance. Furthermore, the increasing awareness regarding organ transplantation and the need for alternative lung support systems during surgeries are driving the demand for artificial lungs. The market is also being boosted by ongoing research and development activities aimed at enhancing the efficiency and efficacy of artificial lungs, which are crucial for patients with severe lung dysfunction. As more innovations emerge, we can expect the market to evolve significantly, meeting the needs of a diverse patient population.

Growth Factor of the Market

The growth of the artificial lung market is primarily driven by the escalating incidence of respiratory diseases, which has been compounded by environmental factors such as air pollution and smoking. The increasing number of patients suffering from Acute Respiratory Distress Syndrome (ARDS) and Chronic Obstructive Pulmonary Disease (COPD) is creating a significant demand for advanced lung support systems. Innovations in technology, such as the development of bioartificial lungs and wearable artificial lung systems, are further fueling market expansion. The rising awareness regarding the benefits of early intervention in respiratory distress situations also contributes to market growth, as healthcare providers seek to provide patients with timely and effective solutions. Additionally, partnerships between healthcare institutions and technology companies to develop cutting-edge artificial lung solutions are expected to bolster market dynamics in the coming years.

Key Highlights of the Market

• The artificial lung market is expected to witness a CAGR of 14.5% from 2025 to 2033.
• Increasing incidence of chronic respiratory diseases is a primary driver of market growth.
• Technological advancements are leading to the development of more efficient artificial lungs.
• The aging population is fueling demand for respiratory support systems.
• Strategic partnerships and collaborations are enhancing product innovation and market reach.

By Product Type

Mechanical Artificial Lung :

Mechanical artificial lungs are devices designed to assist patients with severe respiratory failure, facilitating gas exchange by providing oxygen and removing carbon dioxide. These devices are often used in critical care settings, particularly for patients with ARDS or severe COPD. The mechanical artificial lung employs advanced technology to mimic the natural function of the lungs. Their design has become increasingly sophisticated, featuring improved biocompatibility and reduced complications. As the need for prolonged respiratory support increases, mechanical artificial lungs are expected to see substantial demand in hospitals and intensive care units, where they can effectively save patients' lives during critical situations.

Bioartificial Lung :

Bioartificial lungs utilize living cells to enhance gas exchange, thus providing a more physiological approach to respiratory support. These devices are designed to closely mimic the natural lung environment and are often used in situations where traditional mechanical support may not be sufficient. The use of bioengineered tissues contributes to better oxygenation and carbon dioxide removal, promoting more effective patient outcomes. As research in regenerative medicine progresses, the bioartificial lung segment is likely to grow, attracting investment and attention from medical researchers and healthcare professionals. The potential for personalized treatment approaches using bioartificial lungs is particularly appealing, as it allows for tailored respiratory support strategies.

Hybrid Artificial Lung :

Hybrid artificial lungs combine mechanical and biological components to optimize gas exchange while minimizing complications associated with traditional mechanical ventilators. This innovative product type aims to leverage the advantages of both mechanical support and bioengineering, providing an effective solution for patients with complex respiratory issues. The growing recognition of the limitations of existing mechanical systems has led to increased investment in hybrid technologies. These systems are designed to provide more natural lung functions, enhancing patient comfort and improving clinical outcomes. As the focus shifts towards personalized medicine and patient-centered care, the hybrid artificial lung market is poised for significant growth.

Wearable Artificial Lung :

Wearable artificial lungs represent a breakthrough innovation, allowing patients to receive respiratory support while maintaining mobility. These compact and portable devices can be used at home or during everyday activities, significantly improving the quality of life for individuals with chronic respiratory conditions. The development of wearable technology has driven research into miniaturization and efficient gas exchange mechanisms. As healthcare continues to evolve towards outpatient and home-based care, the demand for wearable artificial lungs is expected to surge, offering patients greater independence and flexibility compared to traditional stationary devices.

Implantable Artificial Lung :

Implantable artificial lungs are designed for long-term use, providing a permanent solution for patients with severe lung failure. These devices are surgically implanted to replace failing lung functions, allowing patients to lead more normal lives without the need for external respiratory support. The development of implantable lungs involves advanced biomaterials and engineering techniques to ensure biocompatibility and minimize rejection risks. While still in the experimental stages, the potential for successful long-term implantation makes this product type a focus of ongoing research. As technology progresses, implantable artificial lungs could become a key solution for patients awaiting lung transplants.

By Application

Acute Respiratory Distress Syndrome :

Acute Respiratory Distress Syndrome (ARDS) is a critical condition characterized by severe respiratory failure, often necessitating advanced lung support. The increasing incidence of ARDS, driven by factors such as pneumonia, sepsis, and trauma, highlights the need for effective respiratory technologies. Artificial lungs play a pivotal role in the management of ARDS by providing essential oxygenation and facilitating carbon dioxide removal. Given the urgency of this condition, the artificial lung market for ARDS applications is expected to grow significantly in the coming years, driven by advancements in technology and improved patient outcomes.

Chronic Obstructive Pulmonary Disease :

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition that causes breathing difficulties and is often associated with long-term exposure to irritants such as smoking and air pollution. The management of COPD may require the use of artificial lungs, particularly in severe cases where patients experience acute exacerbations and require respiratory support. The increasing prevalence of COPD globally, combined with the aging population, is likely to drive demand for artificial lungs tailored for this application. Innovations in lung support technologies are essential to address the complex needs of COPD patients, making this segment a focal point for market growth.

Cystic Fibrosis :

Cystic fibrosis is a genetic disorder that leads to the production of thick, sticky mucus, severely impacting lung function and leading to chronic respiratory infections. Patients with advanced cystic fibrosis often require respiratory support that artificial lungs can provide. As the understanding of cystic fibrosis progresses, the development of specialized artificial lung devices aimed at improving lung function and prolonging life expectancy is gaining traction. The market for artificial lungs in cystic fibrosis applications is expected to expand as awareness of the disease increases and treatment options continue to evolve.

Lung Transplantation Support :

Lung transplantation is a critical intervention for patients with end-stage lung disease, requiring robust support systems to manage respiratory functions during and after the procedure. Artificial lungs serve as essential tools in these situations, providing temporary respiratory support while patients await suitable donor lungs. The demand for artificial lungs in transplantation settings is anticipated to grow as organ donation rates increase and surgical techniques improve. The integration of artificial lungs into transplantation protocols enhances patient safety and outcomes, making this application a key area of focus in the market.

Others :

In addition to the key applications mentioned above, there are various other medical scenarios where artificial lungs can play a significant role. This includes situations like trauma cases, pneumonia management, and respiratory support during major surgical procedures. The versatility of artificial lungs allows them to be used in a range of clinical settings, addressing diverse respiratory support needs. As healthcare systems continue to adapt and find innovative solutions for patient care, the market for artificial lungs across various applications is expected to see sustained growth, driven by ongoing research and technological advancements.

By Distribution Channel

Hospitals :

Hospitals are the primary distribution channel for artificial lungs due to their critical role in providing emergency and acute care. These facilities are equipped with advanced medical technologies and staffed by trained professionals capable of operating complex respiratory support systems. The high demand for artificial lungs in hospital settings is driven by increasing rates of respiratory diseases and the need for urgent interventions, such as in cases of ARDS or severe COPD exacerbations. Hospitals also benefit from the collaborative environment that facilitates the use of multi-disciplinary teams to address complex patient needs, making them a key market for artificial lung manufacturers.

Specialty Clinics :

Specialty clinics focused on respiratory care are increasingly becoming important distribution channels for artificial lungs. These facilities often cater to patients with specific lung conditions, providing tailored treatment options that include advanced respiratory support technologies. The expertise of healthcare professionals in specialty clinics enhances the efficacy of artificial lungs, as these settings often focus on chronic disease management and rehabilitation. As more patients seek specialized care for respiratory diseases, the demand for artificial lungs within these clinics is projected to grow, driven by the need for personalized and targeted therapeutic approaches.

Ambulatory Surgical Centers :

Ambulatory surgical centers (ASCs) offer an alternative setting for surgical and medical procedures, focusing on outpatient care. As more procedures are performed in ASCs, there is an increasing need for effective respiratory support systems, including artificial lungs. These centers often cater to a wide range of patient populations, making them a suitable channel for the distribution of artificial lungs. The growing trend towards outpatient surgeries and the demand for efficient recovery systems will likely drive the adoption of artificial lungs in these facilities, as they seek to ensure optimal patient outcomes.

Online Stores :

The rise of digital health solutions and e-commerce has transformed the way medical devices, including artificial lungs, are distributed. Online stores provide a convenient platform for hospitals, clinics, and individual consumers to access advanced respiratory support technologies. The ability to compare products, read reviews, and access a wider range of options has made online purchasing increasingly popular among healthcare providers. As more manufacturers recognize the potential of e-commerce, the online distribution channel for artificial lungs is expected to expand, enabling broader access to essential respiratory support technologies.

By Technology

Extracorporeal Membrane Oxygenation :

Extracorporeal Membrane Oxygenation (ECMO) is a vital technology used in artificial lungs that allows for the oxygenation of blood outside the body. This technique is particularly beneficial for patients with severe respiratory or cardiac failure, as it provides critical life support by enhancing gas exchange. ECMO systems are designed to mimic the natural lung function, enabling the treatment of various conditions, including ARDS and cardiac arrest. As technology continues to advance, ECMO is expected to become an increasingly common solution in critical care settings, driving the demand for artificial lungs equipped with this technology.

Bioreactor Lung :

Bioreactor lungs represent an innovative approach to artificial lung technology, utilizing living cells and tissues to enhance gas exchange processes. This technology aims to create a more physiologically relevant environment for respiratory support, promoting better outcomes for patients with severe lung conditions. Bioreactor lungs are still under research and development, but their potential to revolutionize lung support therapies is substantial. As the field of regenerative medicine advances, bioreactor lungs could play a significant role in the future of artificial lung systems, attracting interest from both researchers and healthcare providers.

Microfluidic Lung :

Microfluidic lungs employ advanced engineering techniques to create devices that simulate lung functions at a microscale. These systems utilize tiny channels and chambers to facilitate gas exchange, offering a compact and efficient solution for respiratory support. The potential of microfluidic technology in artificial lungs is vast, as it allows for the design of portable, low-profile devices that can be used in various clinical settings. The growing demand for miniaturized medical devices is driving research into microfluidic lungs, and their adoption is expected to increase as healthcare moves towards more patient-friendly solutions.

Biomimetic Lung :

Biomimetic lungs are designed to imitate the natural structure and function of human lungs, incorporating advanced materials and engineering to enhance gas exchange efficiency. These devices aim to replicate the unique physiological processes of the lungs, providing more effective respiratory support for patients with severe lung conditions. As the understanding of lung biology deepens, the development of biomimetic lungs is gaining momentum, attracting investments from both private and public sectors. The appeal of these devices lies in their potential to deliver improved patient outcomes through technology that aligns closely with biological systems.

Nanotechnology :

Nanotechnology is making its mark in the artificial lung sector, with applications that enhance device function and efficiency. By manipulating materials at the nanoscale, researchers are able to develop innovative solutions that improve gas exchange, biocompatibility, and durability of artificial lungs. Nanotechnology can also lead to the creation of smaller, more efficient devices that can be integrated into varied healthcare settings. As the field continues to evolve, the incorporation of nanotechnology into artificial lungs is expected to drive significant advancements, making these devices more accessible and effective for patients requiring respiratory support.

By Region

The North American artificial lung market is anticipated to dominate the global landscape, driven by the presence of advanced healthcare infrastructure, high prevalence of respiratory diseases, and significant investment in medical technology. The United States, in particular, is a key contributor to this market, accounting for a substantial share due to its extensive network of hospitals and specialty clinics. The North American region is expected to grow at a CAGR of approximately 15% during the forecast period, fueled by ongoing innovations in artificial lung technologies and increasing awareness among healthcare providers regarding the benefits of early intervention.

In Europe, the artificial lung market is also poised for considerable growth, attributed to the rising incidence of chronic respiratory diseases and a growing aging population. The European market is characterized by a focus on research and development, with several leading companies investing in innovative technologies to enhance artificial lung performance. The region has been proactive in adopting advanced medical devices, and as healthcare regulations evolve, the uptake of artificial lungs is expected to increase significantly. Combined, these regions are projected to account for a significant share of the global market while ensuring a conducive environment for technological advancements in artificial lung solutions.

Opportunities

The artificial lung market presents a plethora of opportunities driven by the increasing prevalence of respiratory diseases and the growing demand for innovative lung support technologies. With advancements in biotechnology, the development of bioartificial and hybrid artificial lungs offers promising avenues for research and commercialization. These innovations not only enhance patient outcomes but also contribute to the advancement of personalized medicine, allowing for tailored treatment approaches that cater to individual patient needs. Additionally, the rise of telemedicine and remote health monitoring solutions presents unique opportunities to integrate artificial lungs into outpatient care and home healthcare settings, making respiratory support more accessible to patients. Furthermore, as awareness regarding organ donation and transplantation increases, the market is likely to experience growth in demand for artificial lungs as temporary solutions while patients await suitable donors.

Another significant opportunity lies in the collaboration between healthcare providers, research institutions, and technology companies. Strategic partnerships can foster the development of cutting-edge artificial lung technologies, streamline regulatory processes, and enhance market entry strategies. By leveraging collective expertise, these collaborations can translate scientific advancements into practical applications, ensuring that artificial lungs evolve to meet the changing needs of patients and healthcare systems. Moreover, the global focus on improving healthcare infrastructure presents an opportunity for artificial lung manufacturers to expand their reach into emerging markets, where the prevalence of respiratory diseases is rising, and access to advanced medical technologies is becoming increasingly vital.

Threats

Despite the promising growth prospects of the artificial lung market, several threats could hinder its development. One of the primary challenges is the complexity and cost associated with manufacturing advanced artificial lung systems. The materials and technology required for these devices often involve significant research and development investments, which could deter smaller companies from entering the market. Furthermore, the regulatory landscape surrounding medical devices is becoming increasingly stringent, leading to longer approval times and potentially higher costs. This regulatory burden can create barriers to entry for new players and stifle innovation in the field.

Additionally, competition from alternative respiratory support technologies poses a significant threat to the artificial lung market. Non-invasive ventilation (NIV) and other supportive therapies may capture a portion of the market share, particularly in settings where traditional artificial lungs are not feasible or necessary. As healthcare providers aim to deliver cost-effective care, they may opt for simpler solutions, limiting the adoption of advanced artificial lungs. Moreover, the risk of complications and adverse events associated with artificial lung devices can lead to hesitancy among healthcare providers to adopt these technologies, further impacting market growth.

Competitor Outlook

• Medtronic PLC
• Getinge AB
• Thermo Fisher Scientific Inc.
• MediServe Technologies
• Fresenius SE & Co. KGaA
• Xenios AG
• ALung Technologies, Inc.
• Asahi Kasei Medical Co., Ltd.
• Novalung GmbH
• Breathe Technologies, Inc.
• SynCardia Systems, LLC
• Life Support Technologies, Inc.
• HemaCare Corporation
• Roche Diagnostics
• OxyHealth, LLC

The competitive landscape of the artificial lung market is characterized by a blend of established players and emerging innovators, each striving to introduce advanced respiratory support systems. Major companies are focusing their efforts on research and development to enhance the performance and efficiency of artificial lungs, investing heavily in technology to meet the increasing demand for effective respiratory therapies. Additionally, strategic collaborations and partnerships between companies are facilitating the sharing of knowledge and resources, ensuring that new solutions are developed to address the evolving needs of patients. The market is witnessing a trend towards integrated solutions that not only offer support but also incorporate monitoring and diagnostic features, providing comprehensive care to patients with respiratory conditions.

Medtronic PLC is a frontrunner in the artificial lung market, known for its innovative medical technologies and strong focus on patient outcomes. The company has made significant strides in the development of mechanical ventilation systems, and its ongoing commitment to research and development positions it as a key player in the market. Similarly, Getinge AB and Thermo Fisher Scientific Inc. have established themselves as leaders in respiratory care, offering a range of products tailored for critical care settings. Both companies are leveraging their extensive experience and expertise to enhance their artificial lung systems, ensuring that they meet the highest standards of safety and efficacy.

Emerging companies such as ALung Technologies, Inc. and Xenios AG are also making waves in the artificial lung market. These organizations are focused on developing innovative technologies that combine mechanical and biological principles, offering unique solutions like the dialyzer technology and portable ECMO devices. Their dedication to research and innovation allows them to carve out a niche in the market, catering to specific patient populations and challenging traditional approaches to respiratory support. As the artificial lung market continues to expand, these competitors are likely to play a vital role in shaping its future, driving advancements that enhance patient care and treatment outcomes.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Xenios AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Getinge AB
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic PLC
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novalung GmbH
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 OxyHealth, LLC
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 HemaCare Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 MediServe Technologies
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 SynCardia Systems, LLC
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Fresenius SE & Co. KGaA
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 ALung Technologies, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Breathe Technologies, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Asahi Kasei Medical Co., Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Life Support Technologies, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Artificial Lung Market, By Technology
    • 6.1.1 Extracorporeal Membrane Oxygenation
    • 6.1.2 Bioreactor Lung
    • 6.1.3 Microfluidic Lung
    • 6.1.4 Biomimetic Lung
    • 6.1.5 Nanotechnology
  • 6.2 Artificial Lung Market, By Application
    • 6.2.1 Acute Respiratory Distress Syndrome
    • 6.2.2 Chronic Obstructive Pulmonary Disease
    • 6.2.3 Cystic Fibrosis
    • 6.2.4 Lung Transplantation Support
    • 6.2.5 Others
  • 6.3 Artificial Lung Market, By Product Type
    • 6.3.1 Mechanical Artificial Lung
    • 6.3.2 Bioartificial Lung
    • 6.3.3 Hybrid Artificial Lung
    • 6.3.4 Wearable Artificial Lung
    • 6.3.5 Implantable Artificial Lung
  • 6.4 Artificial Lung Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Online Stores

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Artificial Lung Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Artificial Lung market is categorized based on

By Product Type

• Mechanical Artificial Lung
• Bioartificial Lung
• Hybrid Artificial Lung
• Wearable Artificial Lung
• Implantable Artificial Lung

By Application

• Acute Respiratory Distress Syndrome
• Chronic Obstructive Pulmonary Disease
• Cystic Fibrosis
• Lung Transplantation Support
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Online Stores

By Technology

• Extracorporeal Membrane Oxygenation
• Bioreactor Lung
• Microfluidic Lung
• Biomimetic Lung
• Nanotechnology

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic PLC
• Getinge AB
• Thermo Fisher Scientific Inc.
• MediServe Technologies
• Fresenius SE & Co. KGaA
• Xenios AG
• ALung Technologies, Inc.
• Asahi Kasei Medical Co., Ltd.
• Novalung GmbH
• Breathe Technologies, Inc.
• SynCardia Systems, LLC
• Life Support Technologies, Inc.
• HemaCare Corporation
• Roche Diagnostics
• OxyHealth, LLC